FURTHER INFORMATION ABOUT THE GROUP

Incorporation

The Company was established as a limited liability company under the laws of the PRC on July 6, 2012 and was converted into a joint stock company with limited liability on January 8, 2026.

The Company has established a place of business in Hong Kong at 31/F, Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong. The Company was registered as a non-Hong Kong company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and the Companies (Non-Hong Kong Companies) Regulation (Chapter 622J of the Laws of Hong Kong) on March 5, 2026, with Mr. Chow Tsz Ho appointed as the Hong Kong authorised representative of the Company for acceptance of the service of process and any notices required to be served on the Company in Hong Kong.

As the Company was incorporated in the PRC, its operations are subject to the relevant laws and regulations of the PRC. A summary of the relevant aspects of laws and regulations of the PRC and the Articles of Association is set out in "Regulations" and "Appendix III — Summary of the Articles of Association" in this Document, respectively.

Changes in the Share Capital of the Company

Save as disclosed in the section headed "History and Development," there has been no other alteration in the share capital of the Company during the two years immediately preceding the date of this Document.

Subsidiaries of the Company

A summary of the corporate information and the particulars of the Company's subsidiaries are set out in Note 1 to the Accountant's Report as set out in Appendix I to this Document.

There has been no alteration in the share capital of the subsidiaries of the Company within two years immediately preceding the date of this Document.

Resolutions of the Shareholders

On June 26, 2026, resolutions of the Shareholders were passed pursuant to which, among other things:

(i) the Shares be split on a one-for-five basis immediately prior to the [**REDACTED**]. Immediately after the Share Subdivision, the total issued share capital of the Company will be RMB94,623,698 with 473,118,490 Shares with a nominal value of RMB0.20 each;

(ii) the issue by the Company of H Shares with a nominal value of RMB0.20 each and such H Shares be [**REDACTED**] on the Hong Kong Stock Exchange;

(iii) the number of H Shares to be issued shall be no more than [**REDACTED**]% of the total issued share capital of the Company as enlarged by the [**REDACTED**] (before the exercise of the [**REDACTED**]), and the grant of the [**REDACTED**] in respect of no more than [**REDACTED**]% of the number of H Shares issued pursuant to the [**REDACTED**];

(iv) subject to filing with the CSRC, upon completion of the [**REDACTED**], [**REDACTED**] Unlisted Shares held by the existing Shareholders be converted into H Shares on a one-for-one basis (after taking into account the Share Subdivision);

(v) authorization of the Board or its authorized individuals to handle all matters relating to, among other things, the [**REDACTED**], the issue and [**REDACTED**] of H Shares on the Hong Kong Stock Exchange;

(vi) subject to the completion of the [**REDACTED**], the conditional adoption of the revised Articles of Association, which shall become effective on the [**REDACTED**], and the authorization to the Board to amend the Articles of Association in accordance with the requirements of the relevant laws and regulations and the Hong Kong Listing Rules;

(vii) the granting of a general mandate to the Board to (i) allot and issue Shares, and (ii) sell and/or transfer Shares out of treasury that are held as treasury shares, at any time within a period up to the date of the conclusion of the next annual general meeting of the Shareholders or the date on which the Shareholders pass a resolution to revoke or change such mandate, whichever is earlier, upon such terms and conditions and for such purposes as the Board in their absolute discretion deem fit, provided that, the number of Shares to be issued, or to be sold and/or transferred out of treasury that are held as treasury shares shall not exceed 20% of the number of Shares in issue as of the [**REDACTED**] (excluding any treasury shares); and

(viii) the granting of a general mandate to the Board to repurchase H Shares issued on the Hong Kong Stock Exchange with an aggregate number of not exceeding 10% of the number of the total issued H Shares as of the [**REDACTED**] (excluding any treasury shares).

Explanatory Statement on Repurchase of the Company's Own Securities

The following paragraphs include, among others, certain information required by the Hong Kong Stock Exchange to be included in this Document concerning the repurchase of the Company's own securities.

(a) Reasons for repurchase

The Board considered that the repurchase of the Shares would be beneficial to and in the best interests of the Company and its Shareholders as a whole. It can strengthen the investors' confidence in the Company and promote a positive effect on maintaining the Company's reputation in the capital market. Such repurchases will only be made when the Board believes that such repurchases will benefit the Company and its Shareholder as a whole.

(b) Exercise of the general mandate to repurchase H Shares

Subject to the passing of the special resolution approving the grant of the general mandate to repurchase H Shares at annual general meetings, the Board will be granted general mandate to repurchase Shares until the end of the relevant period. The general mandate to repurchase Shares would expire on the earlier of:

(i) the conclusion of the next annual general meeting of the Company of which time it shall lapse unless, by special resolutions passed at that meeting, the authority is renewed, either conditionally or subject to conditions;

(ii) the revocation or variation of the mandate under the resolution by a special resolution at the next general meeting of the Company; or

(iii) the revocation or variation of the mandate under the resolution by a special resolution at any general meeting of the Company.

Furthermore, the Company needs to complete registration and approval procedures with relevant government authorities for the actual grant of the repurchase mandate to the Board, as applicable. The exercise in full of the general mandate to repurchase H Shares (on the basis of [**REDACTED**] H Shares in issue as of the [**REDACTED**] and no H Shares will be allotted and issued or repurchased by the Company on or prior to the date of the next annual general meeting to be held after the [**REDACTED**]) would result in a maximum of [**REDACTED**] H Shares being repurchased by the Company during the relevant period, being the maximum of 10% of the H Shares in issue (excluding any treasury shares) as of the [**REDACTED**].

(c) Source of funds

In repurchasing its Shares, the Company intends to apply funds from the Company's internal resources (which may include surplus funds and retained profits) legally available for such purpose in accordance with the Articles of Association and the applicable laws, rules and regulations of the PRC.

The Company is empowered by its Articles of Association to repurchase its Shares. Any shares to be repurchased will be cancelled or kept as treasury shares if allowed by the Articles of Association and applicable laws and regulations. The Company may not purchase securities on the Hong Kong Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Hong Kong Stock Exchange from time to time.

(d) Suspension of repurchase

A listed company shall not repurchase its shares on the Hong Kong Stock Exchange at any time after inside information has come to its knowledge until the information is made publicly available. In particular, during the period of one month immediately preceding the earlier of: (i) the date of the board meeting (as such date is first notified to the Hong Kong Stock Exchange in accordance with the Hong Kong Listing Rules) for the approval of the company's results for any year, half-year, quarterly or any other interim period (whether or not required under the Hong Kong Listing Rules); and (ii) the deadline for the issuer to announce its results for any year or half-year under the Hong Kong Listing Rules, or quarterly or any other interim period (whether or not required under the Hong Kong Listing Rules), until the date of the results announcement, the company may not repurchase its shares on the Hong Kong Stock Exchange unless there are exceptional circumstances.

(e) Close associates and core connected persons

None of the Directors or, to the best of their knowledge having made all reasonable inquiries, any of their close associates have a present intention, in the event the general mandate to repurchase Shares is approved, to sell any Shares to the Company.

No core connected person of the Company has notified the Company that they have a present intention to sell Shares to the Company, or have undertaken to do so, if the general mandate to repurchase Shares is approved.

A listed company shall not knowingly purchase its shares on the Hong Kong Stock Exchange from a core connected person (namely a director, supervisor (if any), chief executive or substantial shareholder of the company or any of its subsidiaries, or a close associate of any of them), and a core connected person shall not knowingly sell their interest in shares of the company to it.

(f) Status of repurchased Shares

Subject to the Articles of Association, the Hong Kong Listing Rules and any other applicable laws and regulations, the Shares repurchased by the Company will be cancelled or kept as treasury shares.

(g) Takeover implications

If, as a result of any repurchase of Shares, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purposes of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

Save as aforesaid, the Directors are not aware of any consequences which would arise under the Takeovers Code as a consequence of any repurchases pursuant to the general mandate to repurchase Shares.

(h) Interim measures

For any treasury shares of the Company deposited with [**REDACTED**] pending resale on the Hong Kong Stock Exchange, the Company shall, upon approval by the Board, implement the below interim measures which include (without limitation):

(i) procuring its broker not to give any instructions to [**REDACTED**] to vote at general meetings for the treasury shares deposited with [**REDACTED**];

(ii) in the case of dividends or distributions (if any and where applicable), withdrawing the treasury shares from [**REDACTED**], and either re-register them in its own name as treasury shares or cancel them, in each case before the relevant record date for the dividend or distributions; or

(iii) taking any other measures to ensure that it will not exercise any Shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable laws if those Shares were registered in its own name as treasury shares.

(i) General

The Company did not hold any treasury shares as of the Latest Practicable Date and will not hold any treasury shares upon [**REDACTED**].

If the general mandate to repurchase Shares were to be carried out in full at any time, there may be a material and adverse impact on the Company's working capital or gearing position (as compared with the position disclosed in the Company's most recent published audited accounts). However, the Directors do not propose to exercise the general mandate to repurchase Shares to such an extent as would have a material and adverse effect on the Company's working capital or gearing position.

The Directors will exercise the general mandate to repurchase Shares in accordance with the Hong Kong Listing Rules and the applicable laws in the PRC. Neither this explanatory statement on repurchase of the Company's own securities nor the proposed Share repurchase has any unusual feature.

FURTHER INFORMATION ABOUT THE BUSINESS

Summary of Material Contracts

The Group has entered into the following contracts (not being contracts entered into in the ordinary course of business) within the two years immediately preceding the date of this Document that are or may be material:

(a) [**REDACTED**].

Intellectual Property

Trademarks

As of the Latest Practicable Date, the Group had been granted by Fosun Pharma the rights to use the following registered trademarks which are material to the Group's business:

No.	Trademark	Class	Place of Registration	Registration Number
1. .	FOSUN ADGENVAX	1	PRC	62627290
2. .	FOSUN ADGENVAX	5	PRC	62617592
3. .	FOSUN ADGENVAX	10	PRC	62624580
4. .	FOSUN ADGENVAX	35	PRC	62611047
5. .	FOSUN ADGENVAX	39	PRC	62608020
6. .	ADGENVAX	1	PRC	62615150
7. .	ADGENVAX	5	PRC	62607934
8. .	ADGENVAX	10	PRC	62627561
9. .	ADGENVAX	35	PRC	62613076
10.	ADGENVAX	39	PRC	62611087
11.	复星安特金	1	PRC	62616151
12.	复星安特金	5	PRC	62623674
13.	复星安特金	10	PRC	62614581
14.	复星安特金	35	PRC	62624021
15.	复星安特金	39	PRC	62612920
16.	安特金	1	PRC	62615158
17.	安特金	5	PRC	62605745

No.	Trademark	Class	Place of Registration	Registration Number
18.	安特金	10	PRC	62607965
19.	安特金	35	PRC	62613081
20.	安特金	39	PRC	62611092
21.	FOSUN APEXVAC	5	PRC	74418312
22.	FOSUN APEXVAC	10	PRC	74436469
23.	FOSUN APEXVAC	42	PRC	74441045
24.	复星雅立峰	5	PRC	74437806
25.	复星雅立峰	10	PRC	74440704
26.	复星雅立峰	42	PRC	74423877
27.	FOSUN APEXVAC 复星雅立峰	5	PRC	74425543
28.	FOSUN APEXVAC 复星雅立峰	10	PRC	74429309
29.	FOSUN APEXVAC 复星雅立峰	42	PRC	74429338

As of the Latest Practicable Date, the Group had applied for registration of the following trademarks which are material to its business:

No.	Trademark	Class	Applicant	Place of Application	Application Number	Application Date
1.	FOSUN ADGENVAX	5, 10	The Company	Hong Kong	307148692	January 4, 2026
2.	FOSUN APEXVAC	5, 10	The Company	Hong Kong	307148683	January 4, 2026
3.	复星安特金生物	5, 10	The Company	Hong Kong	307148665	January 4, 2026
4.	复星雅立峰生物	5, 10	The Company	Hong Kong	307148656	January 4, 2026
5.	復星安特金生物	5, 10	The Company	Hong Kong	307148647	January 4, 2026
6.	復星雅立峰生物	5, 10	The Company	Hong Kong	307148674	January 4, 2026

Domain Names

As of the Latest Practicable Date, the Group had registered the following domain names which are material to its business:

No.	Domain Name	Registered Owner	Expiry Date
1. .	www.adgenvax.com	The Company	February 14, 2033
2. .	www.adgenvax.cn	The Company	February 7, 2033
3. .	fosunapexvac.com	Fosun Apexvac	July 9, 2026

Patents

As of the Latest Practicable Date, the Group had registered 59 patents and filed 36 patent applications in the PRC. The following patent is material to the Group's business:

No	Patent Name	Type	Patent Holder	Jurisdiction of Registration	Patent Number	Announcement Date
1. .	A Novel Pneumococcal Conjugate Vaccine and Its Preparation Method (一種新的肺炎球菌結合疫苗及其製備方法)	Invention	The Company	PRC	ZL201010129404.2	September 29. 2012

DISCLOSURE OF INTERESTS

Disclosure of Interests of Directors and Chief Executive of the Company

Immediately following the completion of the [**REDACTED**] (assuming the [**REDACTED**] is not exercised), the interests and/or short positions (as applicable) of the Directors and chief executive of the Company in the Shares, underlying Shares and debentures of the Company and any interests and/or short positions (as applicable) in shares, underlying shares or debentures of any of the Company's associated corporations (within the meaning of Part XV of the SFO) which (1) will have to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and/or short positions (as applicable) which they are taken or deemed to have under such provisions of the SFO), (2) will be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein or (3) will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Hong Kong Listing Rules, to be notified to the Company and the Hong Kong Stock Exchange, in each case once the H Shares are [**REDACTED**] on the Hong Kong Stock Exchange, will be as follows:

(i) Interests in the Company

So far as the Directors are aware, immediately following the completion of the [**REDACTED**], no Directors or the chief executive will, directly or indirectly, be interested in the shares or underlying shares of the Company.

(ii) Interests in the associated corporations of the Company

Name of Director or chief executive	Name of associated corporation	Nature of interest	Number and description of shares or underlying shares	Approximate percentage in the relevant type of shares
Mr. Chen Qiyu	Fosun International	Beneficial owner	39,300,400 shares[(1)]	0.48%
	Fosun Pharma	Beneficial owner	114,075 A shares	0.01%
Mr. Wang Kexin	Fosun Pharma	Beneficial owner	20,000 H shares	0.004%
			303,516 A shares	0.01%
Ms. Guan Xiaohui	Fosun International	Beneficial owner	1,600,000 shares[(2)]	0.02%
	Fosun Pharma	Beneficial owner	25,000 H shares	0.005%
			267,743 A shares	0.01%

Notes:

(1) As of the Latest Practicable Date, Mr. Chen Qiyu was interested in (i) 19,730,400 shares of Fosun International directly held by him and (ii) 19,600,000 award shares and options granted to him under the share schemes of Fosun International subject to vesting and/or exercise.

(2) As of the Latest Practicable Date, Ms. Guan Xiaohui was interested in (i) 200,000 shares of Fosun International directly held by her and (ii) 1,400,000 award shares and options granted to her under the share schemes of Fosun International subject to vesting and/or exercise.

Save as disclosed above, so far as the Directors are aware, immediately following the completion of the [**REDACTED**], no Directors or the chief executive will, directly or indirectly, be interested in the shares or underlying shares of the associated corporations of the Company.

Disclosure of Interests of Substantial Shareholders

Save as disclosed above and in "Substantial Shareholders" and "— Disclosure of Interests of Directors and Chief Executive of the Company" in this section, the Directors are not aware of any person (other than a Director or chief executive of the Company) who will have an interest or a short position in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, interested in 10% or more of the issued voting shares of any other member of the Group.

FURTHER INFORMATION ABOUT THE DIRECTORS

Particulars of the Service Contracts

Each of the Directors [has entered] into a service contract with the Company. The principal particulars of these service contracts comprise (a) the term of the service; (b) termination provisions; and (c) dispute resolution provision. The service contracts may be renewed in accordance with the Articles of Association and the applicable laws, rules and regulations from time to time.

Save as disclosed above, none of the Directors has or is proposed to have entered into any service contract with any member of the Group (excluding contracts expiring or determinable by any member of the Group within one year without payment of compensation other than statutory compensation).

Remuneration of Directors

For details of the remuneration of Directors, see "Directors and Senior Management — Remuneration" and Note 8 in "Appendix I — Accountants' Report."

Agency Fees or Commissions Received

The [**REDACTED**] will receive an [**REDACTED**] commission in connection with the [**REDACTED**], as detailed in "[**REDACTED**]." Save in connection with the [**REDACTED**], no commissions, discounts, brokerages or other special terms have been granted by the Group to any person (including the Directors, promoters and experts referred to in "Other Information — Qualifications and Consents of Experts" below) in connection with the issue or sale of any capital or security of the Company or any member of the Group within the two years immediately preceding the date of this Document.

Within the two years immediately preceding the date of this Document, no commission has been paid or is payable for subscription, agreeing to subscribe, procuring subscription or agreeing to procure subscription for any share in or debentures of the Company.

Personal Guarantees

The Directors have not provided personal guarantees in favour of lenders in connection with banking facilities granted to the Group.

Disclaimers

(a) None of the Directors nor any of the experts referred to in "Other Information — Qualifications and Consents of Experts" below has any direct or indirect interest in the promotion of, or in any assets which have been, within the two years immediately preceding the date of this Document, acquired or disposed of by, or leased to, any member of the Group, or are proposed to be acquired or disposed of by, or leased to, any member of the Group.

(b) Save in connection with the [**REDACTED**], none of the Directors nor any of the experts referred to in "Other Information — Qualifications and Consents of Experts" below, is materially interested in any contract or arrangement subsisting at the date of this Document which is significant in relation to the business of the Group.

(c) No cash, securities or other benefit has been paid, allotted or given within the two years preceding the date of this Document to any promoter of the Company nor is any such cash, securities or benefit intended to be paid, allotted or given on the basis of the [**REDACTED**] or related transactions as mentioned.

SHARE INCENTIVE SCHEMES

The Company has adopted share incentive schemes (the "**Share Incentive Schemes**"), and Aopu Yinsuo, Chengdu Jincheng'an and Chengdu Jinshi'an were established in the PRC as the share incentive platforms of the Group (the "**Share Incentive Platforms**"). For details of the Share Incentive Platforms, see "History and Development — Share Incentive Platforms." The Share Incentive Schemes do not involve any grant of Awards (as defined below) after the [**REDACTED**] and therefore is not subject to the provisions of Chapter 17 of the Hong Kong Listing Rules.

Purpose

The purpose of the Share Incentive Schemes is to attract and retain core talents, to establish a mechanism to align the interests of the Shareholders and management, to stimulate entrepreneurial passion among the employees, and to support the Group's long-term development.

Participants

The participants include the directors, supervisors, senior management, core management personnel, core technical personnel and other employees of the Company, its subsidiaries, affiliates and branches, and other persons who make substantial contributions to the development of the Group as recognized by the Board (the "**Participants**").

Awards

Under the Share Incentive Schemes, the Participants have been granted partnership interest in the Share Incentive Platforms (the "**Awards**").

Administration

The Share Incentive Schemes are subject to the approval of the Shareholders' meeting and shall be administered by the Board for, among others, the following matters of the Share Incentive Schemes:

(i) the formulation, amendments and termination of the Share Incentive Schemes;

(ii) the selection of the Participants; and

(iii) the grant of the Awards.

Exercise of voting rights

All management powers and voting rights of each Share Incentive Platform reside with its general partner. All Participants other than the abovementioned general partners do not have any voting rights in the Company. The Participants will be granted Awards in the form of economic interest in the relevant Share Incentive Platforms conditional upon certain vesting conditions as specified in the Share Incentive Schemes and the relevant award agreement.

Restrictions on disposals and vesting period

The lock-up period and vesting conditions of the Awards were stipulated in the Share Incentive Schemes and the relevant award agreement. The Participants may not sell, transfer, pledge, gift or otherwise dispose of the Awards unless the conditions set out in the Share Incentive Schemes and the relevant award agreement are satisfied.

Awards granted under the Share Incentive Schemes

As of the Latest Practicable Date, all of the partnership interest in the Share Incentive Platforms, representing 20,173,705 Shares (after taking into account the Share Subdivision), had been granted to the Participants as incentive under the Share Incentive Schemes. Given the underlying Shares under the Share Incentive Schemes had already been issued to the Share Incentive Platforms, there will not be any dilution effect to the issued Shares upon the vesting of the Awards under the Share Incentive Schemes.

Details of the Awards granted under the Share Incentive Schemes are set out below:

Name	Position(s)	Relevant Share Incentive Platform(s)	Approximate partnership interests in the relevant Share Incentive Platform	Approximate number of Shares corresponding to Awards granted (after taking into account the Share Subdivision)	Approximate shareholding percentage of total issued share capital immediately prior to the [REDACTED]
Mr. Zhang Yuhui	Executive Director and president	Chengdu Jincheng'an	6.64%	879,240	0.19%
Ms. Zhou Lei	Executive Director	Chengdu Jincheng'an	6.04%	799,310	0.17%
Mr. Chen Qiyu	Non-executive Director	Chengdu Jincheng'an	6.64%	879,240	0.19%
Mr. Wang Kexin	Non-executive Director	Chengdu Jincheng'an	12.08%	1,598,620	0.34%

Name	Position(s)	Relevant Share Incentive Platform(s)	Approximate partnership interests in the relevant Share Incentive Platform	Approximate number of Shares corresponding to Awards granted (after taking into account the Share Subdivision)	Approximate shareholding percentage of total issued share capital immediately prior to the [REDACTED]
Ms. Guan Xiaohui .	Non-executive Director	Chengdu Jincheng'an	2.42%	319,725	0.07%
Ms. Chang Mingli .	Chief financial officer	Chengdu Jincheng'an	2.42%	319,725	0.07%
Other grantees[(1)] . .	N/A	Share Incentive Platforms	N/A	15,377,845	3.25%

Note:

(1) Other grantees represent an aggregate of 96 grantees who are not Directors or senior management of the Company.

OTHER INFORMATION

Estate Duty

The Directors have been advised that no material liability for estate duty is likely to fall on the Group.

Litigation

As of the Latest Practicable Date, the Company was not engaged in any outstanding litigation or arbitration which may have material adverse effect on the [**REDACTED**] and, so far as the Directors are aware, no material litigation or claim was pending or threatened by or against the Company.

Joint Sponsors

China International Capital Corporation Hong Kong Securities Limited ("**CICCHKS**") satisfies the independence criteria applicable to sponsors set out in Rule 3A.07 of the Hong Kong Listing Rules.

China International Capital Corporation Limited ("**CICC**"), the parent company of CICCHKS (one of the Joint Sponsors), acted as the independent financial adviser to Fosun Pharma in connection with the [**REDACTED**] and [**REDACTED**] of the Company's H Shares pursuant to the Spin-off Rules for Listed Companies (For Trial Implementation) (《上市公司

分拆規則(試行)》) and the Trial Measures for the Administration on Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》) promulgated by the CSRC.

Notwithstanding the above, considering that (i) the work of the independent financial adviser is a restricted one purely to satisfy the regulatory requirements imposed by the CSRC and the role of financial adviser of CICC is not in conflict with CICCHKS' role as a sponsor for the [**REDACTED**] (such work is also in line with that undertaken by other independent financial advisers in similar [**REDACTED**] cases); and (ii) the fee from the service of independent financial adviser is immaterial, such relationship between CICC and Fosun Pharma would not be reasonably considered to affect CICCHKS' independence as sponsor to the Company in performing its duties, and should not reasonably give rise to a perception that CICCHKS' independence would be so affected under Rule 3A.07(9) of the Hong Kong Listing Rules, and there are no other circumstances affecting CICCHKS' independence under Rule 3A.07 of the Hong Kong Listing Rules.

As of the date of this Document, Fosun International, directly and indirectly through its wholly owned subsidiary, Fosun High Tech, is interested in approximately 36.23% of the total issued ordinary share capital of Fosun Pharma, which in turn indirectly holds approximately 68.47% of the shares in issue of the Company. Fosun International Capital Limited (one of the Joint Sponsors) is an indirect wholly owned subsidiary of Fosun International. As such, taking into account of the indirect shareholding of Fosun International in the Company and Fosun International Capital Limited, Fosun International Capital Limited is not considered as an independent sponsor pursuant to the independence criteria applicable to sponsors set out in Rule 3A.07 of the Hong Kong Listing Rules.

The Company has agreed to pay the Joint Sponsors a total fee of US$900,000 for acting as the sponsors for the [**REDACTED**].

Preliminary Expenses

The Company has not incurred any material preliminary expenses.

Promoters

Within the two years immediately preceding the date of this Document, no cash, securities, or other benefit has been paid, allotted or given, or has been proposed to be paid, allotted or given, to any of the promoters of the Company in connection with the [**REDACTED**] or the related transactions described in this Document.

Qualifications and Consents of Experts

The qualifications of the experts which have given opinions or advice which are contained in, or referred to in, this Document are as follows:

Name of Expert	Qualifications
China International Capital Corporation Hong Kong Securities Limited	A licensed corporation under the SFO for Type 1 (dealing in securities), Type 2 (dealing in futures contracts), Type 4 (advising on securities), Type 5 (advising on futures contracts) and Type 6 (advising on corporate finance) of the regulated activities as defined under the SFO
Fosun International Capital Limited	A licensed corporation under the SFO for Type 1 (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) of the regulated activities as defined under the SFO
Ernst & Young	Certified Public Accountants under the Professional Accountants Ordinance (Chapter 50 of the Laws of Hong Kong) and Registered Public Interest Entity Auditor under the Accounting and Financial Reporting Council Ordinance (Chapter 588 of the Laws of Hong Kong)
Jingtian & Gongcheng	PRC legal advisor
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Independent industry consultant

Each of the experts listed above [has given] and [has not withdrawn] its written consent to the issue of this Document with the inclusion of its report and/or letter (as the case may be) and the references to its name included herein in the form and context in which they respectively appear.

Binding Effect

This Document shall have the effect, if an application is made in pursuance hereof, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of Sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

Bilingual Document

The English language and Chinese language versions of this Document are being published separately, in reliance upon the exemption provided in Section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

Miscellaneous

Save as otherwise disclosed in this section:

(a) within the two years preceding the date of this Document, no share or loan capital of the Company or any of its subsidiaries has been issued or has been agreed to be issued fully or partly paid either for cash or for a consideration other than cash;

(b) no share or loan capital of the Company or any of its subsidiaries is under option or is agreed conditionally or unconditionally to be put under option;

(c) no founder, management or deferred shares of the Company or any of its subsidiaries have been issued or have been agreed to be issued;

(d) save for the H Shares to be converted from the Unlisted Shares and to be issued in connection with the [**REDACTED**], none of the equity and debt securities of the Company or its subsidiary is presently listed or dealt in on any other stock exchange nor is any listing or permission to deal being or proposed to be sought;

(e) the Company has no outstanding convertible debt securities or debentures; and

(f) none of the experts listed under "— Qualifications and Consents of Experts":

    (i) is interested beneficially or non-beneficially in any shares in any member of the Group; or

    (ii) has any right or option (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group save in connection with the [**REDACTED**].